|
Enveric Biosciences Inc (ENVB) |
|
Enveric Biosciences Inc
ENVB's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Enveric Biosciences Inc 's sales fell
in I. Quarter 2024 from the same quarter a year ago.
Major Pharmaceutical Preparations industry recorded
deterioration of revenues by -0.28 %
Enveric Biosciences Inc net loss decreased from $-5 millions, to $-2 millions in I. Quarter 2024,
• More on ENVB's Growth
|
|
Enveric Biosciences Inc realized a net loss in trailing twelve months.
Enveric Biosciences Inc realized cash reduction of $ -1.55 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.76.
• More on ENVB's Valuation
|
|
|
|
|
Enveric Biosciences Inc realized net loss in trailing twelve months.
Enveric Biosciences Inc realized cash outflow of $ -1.55per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.76.
Enveric Biosciences Inc Price to Book Ratio is at 0.25 lower than Industry Avg. of 85.03. and higher than S&P 500 Avg. of 0
• More on ENVB's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2024 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com